8-K: Seres Therapeutics Reports Q1 2024 Results: VOWST Sales Accelerate, Pipeline Progresses

Seres Therapeutics announced its first quarter 2024 financial results, highlighting increased VOWST sales and progress in its SER-155 clinical trial.

Summary

• Seres Therapeutics reported a net loss of $40.1 million for the first quarter of 2024, an improvement from a $71.2 million loss in the same period of 2023.
• VOWST, the company's lead product, generated $10.1 million in net sales during the quarter, with a gross-to-net reduction of approximately 15%.
• Sales of VOWST accelerated in March, reaching $4.6 million, the highest monthly figure since launch, with similar results in April.
• The company received approximately 1,411 completed prescription enrollment forms for VOWST and had approximately 1,083 new patient starts in Q1 2024.
• Research and development expenses decreased to $21.7 million from $44.0 million year-over-year, primarily due to changes in VOWST manufacturing cost recognition and restructuring efforts.
• General and administrative expenses also decreased to $15.5 million from $22.5 million year-over-year, driven by reduced professional fees and personnel costs.
• As of March 31, 2024, Seres had $111.2 million in cash and cash equivalents, compared to $128.0 million at the end of 2023.
• The company anticipates sufficient resources to support operations through obtaining the SER-155 Cohort 2 data and into the fourth quarter of 2024, including a potential $45 million drawdown from an existing debt facility.
• Seres is evaluating options to secure additional capital to advance its pipeline.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The acceleration of VOWST sales and reduction in losses are positive, but the need for additional capital and ongoing losses temper the overall sentiment. The progress in the clinical pipeline is also a positive factor.

Positives

• VOWST sales are showing strong growth, with an acceleration in March and April.
• The number of healthcare providers prescribing VOWST is increasing, indicating broader market adoption.
• The company has successfully completed enrollment for Cohort 2 of the SER-155 Phase 1b study.
• The net loss has significantly decreased year-over-year, indicating improved financial performance.
• Research and development and general and administrative expenses have been reduced, reflecting cost-saving measures.
• The company has sufficient cash to fund operations into the fourth quarter of 2024.

Negatives

• The company reported a net loss of $40.1 million for the quarter.
• Seres' share of the VOWST net loss was $7.1 million.
• Cash reserves decreased from $128.0 million at the end of 2023 to $111.2 million as of March 31, 2024.
• The company is evaluating options to secure additional capital, indicating a potential need for further funding.

Risks

• The company is not currently profitable and may never become profitable.
• Seres relies on third parties to conduct clinical trials and manufacture products.
• The company faces competition in the microbiome therapeutics market.
• There is a risk of transmitting infectious agents due to the nature of VOWST, which is manufactured from human fecal matter.
• The company's ability to protect its intellectual property is a risk.
• The company's ability to retain key personnel and manage growth is a risk.
• The company's operating plans include drawing down the $45 million Tranche B under the Companys existing senior secured debt facility with Oaktree Capital Management, L.P. if the net sales and other conditions are met, as well as alternate plans if such conditions are not met.

Future Outlook

The company anticipates sufficient resources to support operations through obtaining the SER-155 Cohort 2 data and into the fourth quarter of 2024. Seres is also evaluating options to secure additional capital to advance its pipeline.

Management Comments

• Nestl continues to refine its launch execution, and we have seen a resulting acceleration of VOWST sales during March and April, said Eric Shaff, President and Chief Executive Officer of Seres.
• These clinical results could further validate the vast potential of microbiome therapeutics in preventing adverse outcomes linked to gastrointestinal pathogens, continued Mr. Shaff.
• Our goal remains to leverage Seres industry-leading microbiome capabilities to advance the development of SER-155 and other product candidates in additional indications such as chronic liver disease, cancer neutropenia, and solid organ transplants, which could protect millions of medically vulnerable patients from life-threatening infections.

Industry Context

This announcement highlights the growing interest and investment in microbiome therapeutics. Seres' progress with VOWST and SER-155 positions them as a key player in this emerging field, particularly in addressing recurrent C. difficile infections and other medically vulnerable patient populations. The collaboration with Nestl Health Science is also a significant factor in the commercialization of VOWST.

Comparison to Industry Standards

• Seres' VOWST is the first orally administered microbiome therapeutic approved by the FDA for preventing recurrent C. difficile infection, setting a new standard in this area.
• The reported net sales of $10.1 million for VOWST in Q1 2024, while still early in the commercialization phase, are a key metric for comparison against other novel therapeutics in the market.
• The reduction in R&D and G&A expenses reflects a trend in biotech companies to optimize spending as they transition from development to commercialization, similar to companies like Rebiotix (now part of Ferring Pharmaceuticals) which also focuses on microbiome-based therapies.
• The company's focus on expanding the application of its microbiome platform to other indications such as chronic liver disease, cancer neutropenia, and solid organ transplants is a strategy also seen in other companies in the space, such as Vedanta Biosciences, which is developing therapies for various indications.

Management Changes

Related Party Transactions

• Seres shares equally with Nestl, its collaborator, in the VOWST commercial profits and losses.
• Seres share of the VOWST net loss for the first quarter of 2024 was $7.1 million, which was included in the Companys operating results within Collaboration (profit) loss sharingrelated party.

Stakeholder Impact

• Shareholders may be encouraged by the increased VOWST sales and reduced losses, but concerned about the need for additional capital.
• Employees may be affected by the restructuring plan and cost reduction initiatives.
• Healthcare providers and patients benefit from the availability of VOWST for preventing recurrent C. difficile infections.
• Nestl Health Science, as a collaborator, is impacted by the commercial performance of VOWST.

Next Steps

• The company will continue to monitor VOWST sales and market adoption.
• Seres will share a comprehensive topline dataset for the SER-155 Phase 1b study during the third quarter of 2024.
• The company will evaluate options to secure additional capital.
• Seres intends to evaluate SER-155 and other microbiome therapeutic candidates in other medically vulnerable patient populations.

Key Dates

Keywords

VOWST, microbiome therapeutics, Clostridioides difficile infection, SER-155, clinical trial, net sales, financial results, Nestl Health Science, rCDI, FDA Fast Track Designation